Biontech SE banner

Intrinsic Value

The intrinsic value of Biontech SE (22UA) under the Base Case is 43.68 EUR per share. Compared with the current market price of 73 EUR, the stock appears Overvalued by 40% .

The intrinsic value is the average of valuations using the DCF method and multiples.

Do our valuations actually work? See backtest results .

22UA Intrinsic Value
€43.68
Overvaluation 40%
Intrinsic Value
Price €73

22UA is valued in line with its history. A premium of this size has been typical over the past 5 years.

Alert me when 22UA is below its intrinsic value
Today €34.94 · 52.1% below the current price
Alternatives to 22UA

Fundamental Analysis

What Biontech Does

Biotechnology Health Care

BioNTech is a biotechnology company that develops mRNA-based medicines, especially vaccines and cancer treatments. Its best-known product was the COVID-19 vaccine it co-developed with Pfizer, but the company’s main business is broader: it builds drug candidates that teach the body’s immune system to recognize viruses and tumors. It sells approved products where it has them, and it also earns money from partnerships, development payments, and shared profits with larger drug companies.

Headquarters
Germany DE
Employees
7 807
IPO date
Oct 10, 2019
Read the full company overview
View Company Overview

Biontech has no economic moat

No Moat Narrow Wide

Patients and health systems can choose other COVID-19 vaccines without costly lock-in, and Comirnaty does not become more valuable just because more people use it. BioNTech’s oncology medicines are still in development, while its vaccine and cancer-treatment markets have other suppliers, so the company has no current barrier that reliably keeps competitors from winning customers.

Read the full moat analysis
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Latest Earnings Call

Q3 2026 · November 3, 2026

BioNTech raised the midpoint of its 2026 revenue outlook after Q3 and highlighted advancing oncology programs, while reiterating mRNA’s role in its strategy.

Open the earnings call
EPS
$1.94
Expected
$0.85
Surprise
+128.2%
Stock, day of the call
−0.7%
View Earnings Call

Biontech insiders are selling more than usual

Insider trading · Last trade on Oct 9, 2026

Sold $83.3m 2 insiders
Bought $0 Nobody bought
Trades by date
Open insider trading

Insiders sell for many reasons, such as taxes or planned sales; purchases are rarer.

Past 12 months

Continue 22UA Research

Decided on Biontech? Get an email when 22UA reaches the price you’d buy at. Free with an account.

Other Biontech listings

What is the Intrinsic Value of one 22UA stock?

The intrinsic value for Biontech SE (22UA) under the Base Case is 43.68 EUR.

Is 22UA stock undervalued or overvalued?

Compared with the current market price of 73 EUR, the stock appears Overvalued by 40% .

How reliable are our estimates? See how past valuations played out
Back to Top